1418128-33-2

Basic information

• Product Name: 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine
• Synonyms: 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine
• CAS NO: 1418128-33-2
• Molecular Weight: 251.109
• Mol File: 1418128-33-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(1418128-33-2)
• EPA Substance Registry System: 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(1418128-33-2)

Safety Data

• Hazardous Substances Data: 1418128-33-2(Hazardous Substances Data)

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 502496-33-5 1-bromo-5-fluoro-2-methyl-3-nitrobenzene 
• 1418128-32-1 2-(5-fluoro-2-methyl-3-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 502496-36-8 3-bromo-5-fluoro-2-methylbenzenamine 

Downstream Products

• 1418128-35-4 4-[4-(3-amino-5-fluoro-2-methyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide 
• 1418127-62-4 C₃₁H₃₀F₂N₆O₂ 
• 1418128-20-7 C₂₉H₃₆FN₇O₃ 

Relevant articles and documents

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

Deregulation of the receptor tyrosine kinase RET has been implicated in medullary thyroid cancer, a small percentage of lung adenocarcinomas, endocrine-resistant breast cancer and pancreatic cancer. There are several clinically approved multi-kinase inhibitors that target RET as a secondary pharmacology but additional activities, most notably inhibition of KDR, lead to dose-limiting toxicities. There is, therefore, a clinical need for more specific RET kinase inhibitors. Herein we report our efforts towards identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-based drug design. Phenolic anilinoquinazolines exemplified by 6 showed improved affinities towards RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic liability of the phenol led to the discovery that a flanking substituent not only improved the hepatocyte stability, but could also impart a significant gain in selectivity. This culminated in the identification of 36; a potent RET inhibitor with much improved selectivity against KDR.

LABELED AMINO PYRIMIDINE DERIVATIVES

The present invention describes novel radioactive amino pyrimidine derivatives, their preparation and their use as radiotracers / radiomarkers for imaging techniques and as diagnostic tools in the field of BTK receptor susceptible diseases and/or disorder